Litcius/Paper detail

Lipid-Nanopotentiated Combinatorial Delivery of Tamoxifen and Sulforaphane: <i>Ex Vivo</i> , <i>In Vivo</i> and Toxicity Studies

Bharti Mangla, Yub Raj Neupane, Archu Singh, Pankaj Kumar, Sadat Shafi, Kanchan Kohli

2020Nanomedicine47 citationsDOI

Abstract

Aim: This study aims to load tamoxifen (TAM) and sulforaphane (SFN) into nanostructured lipid carriers (NLCs) to enhance their oral delivery. Materials & methods: TAM-SFN-NLCs were prepared using Precirol® ATO5 and Transcutol® HP, characterized and evaluated in vitro and ex vivo to assess the drug release profile and intestinal permeability, respectively. In vivo pharmacokinetic and acute toxicity assessment was performed in Wistar rats. Results: Optimized TAM-SFN-NLCs exhibited a particle size of 121.9 ± 6.42 nm and zeta potential of -21.2 ± 2.91 mV. The NLCs enhanced intestinal permeability of TAM and SFN and augmented oral bioavailability of TAM and SFN 5.2-fold and 4.8-fold, respectively. SFN significantly reduced TAM-associated toxicity in vivo. Conclusion: This coencapsulation of a chemotherapeutic agent with a herbal bioactive in NLCs could pave a novel treatment approach against cancer.

Topics & Concepts

Ex vivoSulforaphaneIn vivoPharmacologyToxicityChemistryTamoxifenMedicineBiologyBiochemistryInternal medicineBiotechnologyCancerOrganic chemistryBreast cancerAdvancements in Transdermal Drug DeliveryCurcumin's Biomedical ApplicationsNigella sativa pharmacological applications